It was noticed that apigenin combined with gefitinib inhibits multiple oncogenic drivers including HIF-1α, EGFR, c-Myc, and reduces MCT1 and Gluts protein expression, Consequently, the combined apigenin + gefitinib treatment grants an attractive strategy as an alternative treatment for the acquired resistance to epidermal growth factor receptor -TKIs in lung cancer [54]. This evidence concerns the gene EGFR and lung cancer.